|
1. Biologie
|
|
|
|
|
Breast cancer spread 'trigger' discovered [The Guardian]
|
|
|
|
|
|
The
team’s latest research found that macrophages require signalling
molecules called chemokines to communicate with breast cancer cells. But
when scientists blocked these signals in mice, they found the number of
secondary tumours in the lungs was reduced by up to two-thirds.
|
|
|
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
|
3.1 Tabac
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
|
|
New Ways Doctors Reach Agreement on Patient Diagnoses [Wall Street Journal]
|
|
|
|
|
|
Hardeep
Singh, a patient safety researcher at the Michael E. DeBakey VA Medical
Center and Baylor College of Medicine in Houston, says the entire
system of specimen collection, processing and interpretation needs to be
improved. He says pathologists should be part of the medical team and
“not siloed as much from the rest of patient care.”
|
|
|
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.2 Pharma
|
|
|
|
|
Novartis places big, broad bet on cancer immunotherapy [Reuters]
|
|
|
|
|
|
But
while the likes of Bristol-Myers Squibb, Merck, Roche and AstraZeneca
have recently focused on checkpoint inhibitor drugs, Novartis has put
most of its effort behind a cell-based immunotherapy known as CAR-T. Now
it is broadening its bet on different ways to harness the body's immune
system to fight tumors, including a sharp ramp-up in checkpoint
inhibitor work.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
EMA Reflects on Advanced Therapy Classification [RAPS]
|
|
|
|
|
|
In
the EU, medicinal products derived from genes, cells or tissues are
classified as ATMPs. Because these areas of biomedicine are still in
early stages of development and are fundamentally different from other
types of medicine, the European Commission (EC) regulates them
differently.
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
|
Paying For Faster Peer Review [In the Pipeline]
|
|
|
|
|
|
I
think that most scientists can agree that the current peer-review
system is probably not the best of all possible worlds - Doctor Pangloss
never had to deal with the dreaded Third Reviewer, especially when the
whole process took about six months. Whether there's anything better,
though, has been a subject of much debate. I definitely appreciate NPG's
willingness to experiment, and I wish that other scientific publishers
were doing the same.
|
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.8 Communication
|
|
|